Literature DB >> 26631178

Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.

Fei Liu1, Lina Gu2, Yu Cao1, Xiaojie Fan2, Fengjuan Zhang3, Meixiang Sang1,2.   

Abstract

It has been reported that the trimethylation of histone 3 on lysine 27 (H3K27me3) is required for enhancer of zeste homology 2 (EZH2)-mediated repression of various genes essential for tumorigenesis and tumor development. Here, we reported the expression of EZH2 and H3K27me3 in esophageal squamous cell carcinoma (ESCC) specimens was higher than the pericarcinoma esophageal specimens. Their expression was positively associated with the poor prognosis of ESCC patients. EZH2 expression, histological grade and distant lymph node metastasis were all independent factors for poor prognosis of ESCC. In addition, enforced expression of EZH2 in esophageal cancer-derived cells could increase the overall H3K27me3 level. Our results suggested the expression of EZH2 and H3K27me3 could serve as biomarkers in the prediction of ESCC patients' survival and ESCC metastasis.

Entities:  

Keywords:  Enhancer of zeste homology 2; esophageal squamous cell carcinoma; histone 3 on lysine 27; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26631178     DOI: 10.3109/1354750X.2015.1118537

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  24 in total

Review 1.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC.

Authors:  Ziqiang Tian; Zhenhua Li; Yonggang Zhu; Lingjiao Meng; Fei Liu; Meixiang Sang; Guiying Wang
Journal:  Clin Exp Metastasis       Date:  2019-06-13       Impact factor: 5.150

3.  H3K27 trimethylation and H3K9 dimethylation as poor prognostic markers for patients with esophageal squamous cell carcinoma.

Authors:  Shaofeng Lin; Menghan Zhou; Yiping Li; Yanping Chen; Weizhang Xu; Wenjia Xia; Siwei Wang; Rong Yin; Qin Zhang; Lin Xu; Hong Fan
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

4.  Predicting the Correlation of EZH2 and Cancer Stem Cell Markers in Esophageal Squamous Cell Carcinoma.

Authors:  GholamReza Karami Madani; Abolfazl Rad; Mehdi Molavi; Sima Ardalan Khales; Mohammad Reza Abbaszadegan; Mohammad Mahdi Forghanifard
Journal:  J Gastrointest Cancer       Date:  2018-12

Review 5.  Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Authors:  Cui Wu; Wu Song; Zhongnan Wang; Bingmei Wang
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

6.  Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia.

Authors:  Phetmany Sihavong; Nakarin Kitkumthorn; Natchalee Srimaneekarn; Dusit Bumalee; Puangwan Lapthanasupkul
Journal:  Head Neck Pathol       Date:  2020-07-27

Review 7.  Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients.

Authors:  De-Chen Lin; Ming-Rong Wang; H Phillip Koeffler
Journal:  Gastroenterology       Date:  2017-07-27       Impact factor: 33.883

8.  EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma.

Authors:  Tongle Zhi; Tianfu Yu; Minhong Pan; Er Nie; Weining Wu; Xiefeng Wang; Ning Liu; Yongping You; Yingyi Wang; Junxia Zhang
Journal:  Oncotarget       Date:  2017-10-24

9.  Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells.

Authors:  Yuting Gu; Jing Zhang; Huai Guan
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 3.111

10.  Expression of EZH2 in uveal melanomas patients and associations with prognosis.

Authors:  Ying Cheng; Ying Li; Xin Huang; Wenbin Wei; Yi Qu
Journal:  Oncotarget       Date:  2017-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.